Gene-editing firms form patent alliance against Editas, Broad
By Max Stendahl,
Boston Business Journal
| 12. 16. 2016
Four biotechs involved in the burgeoning field of gene editing announced a formal patent alliance on Friday that puts them at odds with two Cambridge institutions doing the same, Editas Medicine and The Broad Institute.
The four companies — Berkeley, California-based Caribou Biosciences, ERS Genomics of Ireland, and Cambridge-based firms CRISPR Therapeutics (Nasdaq: CRSP) and Intellia Therapeutics (Nasdaq: NTLA) — all licensed or sublicensed intellectual property regarding CRISPR/Cas9 gene-editing from the same source: biologist Emmanuelle Charpentier, the Regents of the University of California and the University of Vienna.
On the other side of the dispute is Editas (Nasdaq: EDIT), which has been using CRISPR technology developed by Feng Zhang of the Broad Institute.
Charpentier and Zhang have each received patents for CRISPR/Cas9, a method of cutting out and replacing part of a gene that has the potential to revolutionize the treatment of serious genetic disorders. Their backers — UC Berkeley and the Broad, respectively — are currently duking it out in a court case in Virginia before the U.S. Patent and Trademark Office. A decision is expected in coming...
Related Articles
By Gemma Conroy, Nature | 06.27.2024
Image by Robina Weermeijer from Unsplash
A molecular-editing tool that’s small enough to be delivered to the brain shuts down the production of proteins that cause prion diseases, a rare but deadly group of neurodegenerative disorders.
The system — known...
By Julia Black and Margaux MacColl, The Information [cites CGS' Katie Hasson] | 07.19.2024
When venture capitalist Jack Abraham first began dating his wife, Gabriella Massamillo, he insisted on one condition: that when they were ready to have children, she’d be willing to conceive using in vitro fertilization. Abraham had lost both his mother...
By Kevin Davies, Genetic Engineering & Biotechnology News | 06.27.2024
Physician-scientist Matthew Porteus, MD, PhD, has been a mainstay in the genome editing field for more than two decades. He trained at Stanford University Medical School before completing his residency and hematology/oncology fellowship at Boston Children’s Hospital/Dana Farber Cancer Institute...
By Robert F. Service, Science | 07.04.2024
Image by Ed Uthman from Flickr
Last year, the U.S. Food and Drug Administration (FDA) approved two gene therapy procedures that can treat and, in some cases essentially cure sickle cell disease, a genetic blood disorder that causes pain and...
